Engflag

Бифрен

Quick links to important sections

Бифрен

Selected form

Bifren_RU

Method of action: Nootropic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Бифрен

Property Description
Active ingredient Phenibut (beta-Phenyl-gamma-aminobutyric acid)
Form Oral tablets or capsules
Pharmacological class Neuropsychotropic agent (Tranquilizer, Nootropic)
General purpose Managing tension, anxiety, and supporting cognition
Origin Synthetic derivative, developed in Russia/Soviet Union

What is Бифрен and its Active Substance, Phenibut?

Бифрен is a medicinal product based on the single active substance, Phenibut, known chemically as beta-phenyl-gamma-aminobutyric acid. This compound is a synthetic aromatic amino acid derivative with established use in Eastern European contexts, where it originated in the 1960s. Phenibut is typically taken orally in tablet or capsule form. The compound’s unique structure, which includes a phenyl group, is considered a factor in its ability to cross the blood-brain barrier effectively, allowing it to modulate nervous system activity.

Pharmacological Classification: Tranquilizer and Nootropic

Бифрен is classified as a neuropsychotropic agent with a dual functional identity, recognized as both a mild tranquilizer (anxiolytic) and a nootropic agent. Phenibut belongs to the category of psycho-stimulants and nootropics. Phenibut functions as a GABA agonist, a central nervous system depressant, and an anxiolytic. The medicine is intended to help slow certain brain activities, providing a calming and anxiety-reducing effect for managing emotional stress.

General Purpose: Managing Tension and Supporting Cognition

The general purpose of the medicine is to offer a stabilizing effect on the nervous system, aimed at managing feelings of tension and anxiety. By modulating inhibitory neural pathways, the compound promotes a state of balanced activity. The substance is used to ease emotional stress and improve cognitive function in various conditions. The compound’s dual action is therefore directed toward normalizing the patient's emotional state and optimizing mental processing, differentiating its intended benefit from agents that cause pronounced sedation.

What side effects are possible with Бифрен?

Possible Side Effects and Safety Information

Бифрен (Phenibut) is generally considered well-tolerated at therapeutic doses, but as a central nervous system (CNS) active substance, it carries a risk of side effects, dependence, and severe withdrawal, especially with prolonged use or high doses.

Common Side Effects

Side effects that are more frequently observed, particularly at the start of treatment or with increased dosage, are typically related to its CNS depressant activity. These may include:

  • Sedation and Drowsiness: Feeling sleepy or excessively relaxed.
  • Nausea: Stomach discomfort.
  • Dizziness: A feeling of lightheadedness or unsteadiness.
  • Headache: Mild to moderate head pain.
  • Irritability or Agitation

Serious Side Effects and Risks

Consult a healthcare professional immediately if you experience any severe or unusual reactions, including motor incoordination, confusion, loss of balance, or signs of an allergic reaction (e.g., skin rash, itching).

  • Tolerance and Dependence: Regular, prolonged use, even at therapeutic doses, can quickly lead to tolerance, requiring higher doses for the same effect. This can result in physical and psychological dependence.
  • Withdrawal Syndrome: Abrupt discontinuation, particularly after chronic use or high-dose intake, can trigger a severe withdrawal syndrome. Symptoms may include rebound anxiety, severe insomnia, tremors, tachycardia (rapid heart rate), hallucinations, and, in rare, severe cases, seizures or psychosis.
  • Overdose: Ingestion of very high doses can lead to severe CNS depression, resulting in pronounced drowsiness, low blood pressure, vomiting, and, in extreme cases, respiratory depression and reduced consciousness or coma.

Contraindications and Interactions

This medication is contraindicated in individuals with known intolerance to phenibut, acute liver failure or insufficiency, and active ulcerative lesions of the gastrointestinal tract. It should be avoided during pregnancy and breastfeeding and is generally not recommended for children under the age of two.

Critical Drug Interactions: Do not combine this product with other CNS depressants, as this greatly increases the risk of severe adverse effects, including respiratory depression. This includes:

  • Alcohol
  • Sedative/Hypnotic medications
  • Opioids

Patients taking other medications should always consult their physician before starting treatment to avoid dangerous interactions.

Overdose and Emergency Response

Overdose of the active substance Phenibut is documented in regulatory and public health reports as presenting a risk for severe toxicity, primarily involving the central nervous system. Immediate emergency medical assistance is required for any suspected overdose due to the potential for life-threatening outcomes.

Documented Manifestations and Severe Outcomes

Overdose manifestations officially documented in surveillance and toxicity reports include a spectrum of Central Nervous System (CNS) Depression, characterized by reduced consciousness, somnolence, confusion, stupor, or complete unresponsiveness. Other observed signs include agitation, slurred speech, and motor incoordination.

Severe toxicity can progress to major life-threatening outcomes, specifically coma, respiratory depression requiring supportive care, and the occurrence of tonic-clonic seizures. The cardiovascular system may also be affected, with reports of severe hypotension or tachycardia. High-dose exposure has also been associated with organ damage, including renal impairment.

Emergency Actions and Management

Immediate medical attention is required for any severe symptoms, including loss of consciousness, difficulty breathing, or seizure activity. Contacting emergency medical services is the mandated action in these critical scenarios.

No specific antidote is known for Phenibut overdose. Therefore, management is symptomatic and supportive. Clinical procedures documented in the overdose context include gastrointestinal decontamination, such as gastric lavage or the administration of activated charcoal. Patients presenting with severe toxicity may require continuous observation and monitoring, often necessitating intensive care unit (ICU) management. Reports indicate that unintentional exposures are commonly seen in persons under 18 years of age.

Therapeutic Uses of Бифрен

What Бифрен Treats: Main Uses and Benefits

The application of Бифрен (Phenibut) generally relates to supportive symptomatic management across neurological and psychological domains, particularly as utilized in established regional medical practices. This medication is commonly used across conditions presenting with periods of heightened symptoms, including neurotic and anxiety disorders, asthenic states, vestibular dysfunction (such as Ménière's disease), and certain pediatric motor disturbances (like stuttering and tics).

The primary therapeutic support is associated with easing emotional tension and may assist with functional stability. It is often applied during phases of increased distress or discomfort, relevant in conditions where symptoms may intensify temporarily. The therapy is intended to assist in managing emotional tension, fear, and irritability, and contributes to supporting cognitive function during periods of high intellectual strain.

“The drug is applied when groups of symptoms create noticeable functional strain, offering supportive relief that may assist patients in coping more steadily.”

This provides symptomatic assistance that contributes to improved comfort during symptomatic periods.

Quick Fact: Symptomatic Support for Anxiety, Asthenia, and Vertigo The therapeutic support provided by this medication is commonly used to help with symptoms related to heightened physiological activity and those linked to organ-specific functional stress, assisting in the management of emotional lability, fatigue, and balance issues.

Eligibility and Restrictions for Use

Official Population Eligibility for Бифрен

The official regulatory profile for Бифрен strictly defines eligibility based on age, organ health, and physiological status, as stated in its licensed instructions for use.

Absolute Contraindications (Prohibited Use): Use is absolutely prohibited for patients with Hypersensitivity to Phenibut or any component of the drug. The medicine is formally contraindicated in cases of Acute Renal Insufficiency.

Age-Related and Reproductive Eligibility: Use is strictly prohibited for Children under 8 years of age. Furthermore, the medicine is officially contraindicated for Women during Pregnancy and the period of Lactation due to insufficient safety data documented for these groups.

Conditional Use Mandates: Eligibility is restricted for certain populations. Patients with Liver Insufficiency or Pathologies of the Digestive Tract must only be prescribed the smallest effective doses to meet official conditional use requirements. Similarly, Older Adults (60 years and over) are subject to a regulated maximum single dose restriction detailed in the product labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the documented interaction patterns for Бифрен (Phenibut) as described in authoritative regulatory sources and scientific reports detailing its authorized use.

Documented Interaction Profile

The primary interaction pattern for this product involves pharmacodynamic potentiation with substances that affect the central nervous system (CNS). This interaction is strictly based on the additive effects of co-administered compounds, rather than metabolic enzyme pathways.

Interaction Type Interacting Substances / Classes Official Description of Outcome
Pharmacodynamic Potentiation CNS Depressants (Anxiolytics, Sedatives, Opioids, Anticonvulsants) Co-administration may mutually potentiate and extend the duration of central depressant effects, increasing the risk of enhanced sedation.
Substance-Specific Reinforcement Alcohol (Ethanol), Tetrahydrocannabinol (THC) Documented to cause a pharmacodynamic reinforcement of CNS depressant effects.

Regulatory Constraints

The interaction profile dictates that the concurrent use of CNS depressants or alcohol must be noted due to the risk of additive depressant effects. There are no widely documented or universally mandated regulatory requirements for dose timing separation (e.g., administering doses 'X' hours apart) in the official prescribing information.

Regulatory documentation does not formally describe interactions involving Cytochrome P450 (CYP) enzymes or drug transporters. Similarly, no specific interaction cautions related to patient populations, such as those with hepatic or renal impairment, are explicitly noted in the official regulatory data.

Mechanism of Action

The mechanism of action for Phenibut (the active ingredient in Бифрен) is defined by its capacity to enhance central nervous system (CNS) inhibition through two distinct, yet complementary, molecular pathways, leading to a dual mechanism that reduces neuronal hyperexcitability.

Dual Inhibition through Molecular Targets

The drug functions as a direct full agonist at the GABA B receptor, which initiates an inhibitory cascade involving G-proteins that cause the postsynaptic neuron to hyperpolarize. Simultaneously, the molecule modulates the alpha2delta subunit of presynaptic Voltage-Dependent Ca^2+ Channels (VDCCs), reducing the required calcium influx for excitatory neurotransmitter release. This combined action results in a pronounced reduction in the rate of action potential generation.

Resulting Neural Stabilization and Functional Constraint

The dual inhibitory action—acting on both postsynaptic ( GABA B) and presynaptic ( VDCC) terminals—produces a net effect of reduced systemic neural excitation. This physiological change affects circuits associated with afferent sensory processing within the CNS. A key constraint of this mechanism is the potential for GABA B receptor downregulation due to continuous agonism, which leads to functional tolerance and reduces the efficacy of the inhibitory mechanism over time.

Dosage and Administration Information

The administration of Бифрен (Phenibut) is based on established protocols. Its use is managed as a prescription-only medicine. These protocols detail the available routes, dosage forms, and specific scheduling requirements.

Official Administration Guidelines

The standard administration parameters structure the proper use of the drug:

Administration Parameter Official Guideline
Route and Form Primarily Oral (tablets/capsules, with available unit strengths including 250 mg and 500 mg). The Intravenous route is an option for the solution form (10 mg/mL).
Dosing Schedule Adult daily regimens commonly adhere to a total dose ranging from 500 mg to 1,500 mg, depending on the specific application. This dose is precisely determined by the prescribing specialist.
Frequency Pattern The total daily dose must be administered using a divided regimen, necessitating multiple separate administrations throughout the day to support consistent concentrations.
Course Duration Use is generally limited to defined, short-term courses or treatment cycles, and is not for continuous, indefinite long-term maintenance.
Special Conditions Administration occurs exclusively within a prescription-only framework, requiring professional oversight throughout the treatment period.

The established protocol involves the total daily dosage being administered via divided oral doses using the available unit strengths. The protocol is structured around short-term courses, establishing boundaries on the duration of use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Summary

Research has examined the compound as a focus area for acute pain investigation, including exploration of its profile in post-operative recovery and the concurrent use of strong opioids. Investigation into its practical applicability remains ongoing. Studies examined whether the combination yielded different results when assessed across various pain models.

Primary Clinical Research: Acute Pain

Initial investigations have focused on the drug's profile when studied in post-surgical pain. Specifically, randomized controlled trials (RCTs) have documented its evaluation in orthopedic, abdominal, and dental procedures.

Research Focus Primary Outcome Measured
Post-Operative Pain Measurement of mean pain scores over a 72-hour period.
Co-analgesic Use Difference in total opioid consumption compared to control group.

Research explored whether the combination resulted in lower reported pain intensity compared to placebo; findings were mixed when compared with non-opioid active comparators.

Headache and Chronic Pain Exploration

Studies have evaluated its use in non-surgical pain conditions. Research has investigated the findings related to headache and muscle pain in the studies, including the time course of any observed difference. Current evidence remains restricted to short-term assessment in chronic pain states.

Safety Profile and Suitability

Safety has been evaluated in various populations, with ongoing research into specific patient groups. Investigations into use by people with liver conditions remain ongoing. Continued research is necessary to fully characterize the drug’s profile.

Frequently Asked Questions (FAQ)

Common questions about Бифрен (FAQ)

Q: What is the chemical classification of the drug?

A: The active substance in this medicine, Phenibut, is chemically classified as a phenyl derivative of gamma-aminobutyric acid ( GABA). This structure makes it similar to GABA, which is a naturally occurring inhibitory messenger in the brain. Authoritative chemical information typically refers to the compound as a GABA analog.

Q: How long does it take for the medicine to start working after the first dose?

A: Studies and official information indicate that the onset of effects after taking an oral dose of Phenibut is typically reported to occur within 2 to 4 hours. This timeline is based on published pharmacokinetic data, which tracks how the body absorbs and distributes the medicine.

Q: Is there a special warning for operating vehicles or machinery?

A: Official product information suggests exercising caution when engaging in activities that require full mental alertness. This is due to the possibility of central nervous system ( CNS) depressant effects, such as drowsiness, dizziness, and motor incoordination, which carries a risk of impaired performance for activities such as operating heavy machinery or driving.

Q: What do I do in case of an accidental overdose?

A: An overdose of this medicine is considered a medical emergency. Ingestion of very high doses can lead to severe CNS depression and respiratory issues. Regulatory warnings state that professional medical help or poison control should be contacted immediately if an overdose is suspected.

Q: How long is the course of treatment, or when should I stop taking it?

A: According to the official administration guidelines, the use of this medicine is strictly restricted to defined, short-term courses or treatment cycles. The duration of the treatment is determined by the prescribing specialist and is subject to the course length established by them, which should not be exceeded.

How should Бифрен be stored and disposed of?

How to Store and Dispose of Бифрен (Bi-Fren)

Official regulatory documents define specific requirements for storing and disposing of this medicine to maintain its stability and effectiveness.

Storage Conditions:

Requirement Instructions
Temperature Store below 25 C (or at controlled room temperature).
Protection Keep the product in the original carton or blister packaging to protect it from light and moisture.
Handling Do not freeze or refrigerate the medicine.
Child Safety Keep this medicine strictly out of the sight and reach of children.

Disposal Protocol:

Official instructions prohibit disposing of Бифрен via household waste or wastewater. To ensure environmental protection and proper management of unused or expired medicine, users should return the product to a pharmacist or designated pharmaceutical collection point for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagUkraine

Equivalent of Бифрен found in:

A-Z Index: